The Importance of Systematic Screening
Patient selection is among the most critical determinants of safety in low-dose ketamine therapy. While ketamine has a wide therapeutic index and a well-characterized safety profile at subanesthetic doses, specific medical and psychiatric conditions can substantially increase the risk of adverse outcomes. A structured, evidence-based screening process ensures that patients who stand to benefit from ketamine are identified while those for whom the risks outweigh the benefits are appropriately redirected to alternative treatments.
Screening should be comprehensive, encompassing a detailed medical and psychiatric history, focused physical examination, relevant laboratory studies, and a thorough informed consent discussion. The screening process is not merely a checkbox exercise but rather a clinical assessment that requires sound medical judgment. For a comprehensive discussion of how to select appropriate candidates, see the patient selection criteria framework., particularly when evaluating relative contraindications where risk-benefit calculations are nuanced and individualized.
Absolute Contraindications
Certain conditions represent absolute contraindications to ketamine therapy in virtually all clinical contexts. These include situations where ketamine's pharmacological effects pose an unacceptable risk of serious harm.
Uncontrolled Hypertension
Ketamine produces dose-dependent sympathomimetic activation, resulting in elevations of systemic blood pressure and heart rate. In patients with uncontrolled hypertension, defined as systolic blood pressure persistently above 180 mmHg or diastolic blood pressure above 110 mmHg despite treatment, ketamine administration risks precipitating hypertensive crisis, cerebrovascular accident, or acute cardiac events. Patients with hypertension should have their blood pressure optimized before initiating ketamine therapy.
Active Psychotic Disorders
Ketamine's NMDA receptor antagonism can exacerbate psychotic symptoms, including hallucinations, delusions, and disorganized thinking. Patients with active schizophrenia, schizoaffective disorder in a psychotic phase, or any other condition characterized by active psychosis should not receive ketamine. This contraindication is based on both the pharmacological mechanism and clinical reports of psychotic exacerbation following ketamine exposure.
Known Hypersensitivity
A documented history of anaphylaxis or severe allergic reaction to ketamine or any component of the formulation is an absolute contraindication. True ketamine allergy is rare but has been reported.
Conditions with Elevated Intracranial Pressure
Although the historical concern about ketamine increasing intracranial pressure (ICP) has been substantially revised by more recent evidence, patients with known unstable intracranial hypertension due to mass lesions, obstructive hydrocephalus, or acute intracranial hemorrhage should not receive ketamine outside of carefully controlled neurosurgical or critical care settings.
Relative Contraindications
Relative contraindications require individualized risk-benefit assessment and may necessitate additional precautions, modified dosing, or enhanced monitoring rather than absolute exclusion.
Cardiovascular Disease
Patients with stable coronary artery disease, congestive heart failure, or arrhythmias may receive ketamine with caution. Pretreatment cardiac evaluation, including electrocardiography, and coordination with the patient's cardiologist are recommended. Continuous cardiac monitoring during infusions should be considered for patients with significant cardiovascular comorbidity.
History of Psychotic Symptoms
Patients with a remote history of psychotic episodes, psychotic features during previous mood episodes, or a first-degree family history of schizophrenia represent a gray area. While active psychosis is an absolute contraindication, patients with well-controlled psychotic disorders on stable antipsychotic regimens or with psychotic features only in the context of severe mood episodes may be considered for ketamine on a case-by-case basis with close psychiatric monitoring.
Substance Use Disorders
Ketamine has known abuse potential, and patients with active substance use disorders, particularly those involving dissociative drugs, phencyclidine, or other NMDA antagonists, require careful evaluation. A history of substance use disorder in sustained remission is not an absolute contraindication, but enhanced screening for misuse behaviors and more frequent clinical assessments are prudent. Patients in active ketamine or PCP misuse should not receive therapeutic ketamine.
Pregnancy and Lactation
Data on ketamine safety during pregnancy are limited. Animal studies have raised concerns about neurodevelopmental toxicity at high or prolonged exposures, and ketamine crosses the placenta readily. Ketamine therapy should generally be deferred during pregnancy unless the clinical situation is emergent and no safer alternatives exist. Limited data suggest low-level ketamine excretion into breast milk, warranting caution in lactating patients.
Hepatic Impairment
Significant liver disease may prolong ketamine exposure due to reduced hepatic clearance. Patients with Child-Pugh class B or C cirrhosis require dose adjustments and extended monitoring. Liver function testing should be performed as part of baseline screening.
Recommended Screening Protocol
Medical History and Review of Systems
A thorough medical history should specifically address cardiovascular disease, hypertension, hepatic and renal function, seizure history, thyroid disease (hyperthyroidism may amplify sympathomimetic effects), glaucoma (ketamine may increase intraocular pressure), and any history of allergic reactions to anesthetic agents.
Psychiatric Evaluation
The psychiatric evaluation should document the current diagnosis, symptom severity using validated rating scales, treatment history, and specific screening for psychotic symptoms (current and historical), active suicidality with imminent plan or intent, mania or hypomania, and substance use disorders. Structured instruments such as the Columbia Suicide Severity Rating Scale (C-SSRS) and the MINI International Neuropsychiatric Interview can standardize this assessment.
Baseline Laboratory and Diagnostic Studies
Recommended baseline studies include a comprehensive metabolic panel to assess hepatic and renal function, thyroid function tests, urine drug screen, pregnancy test for patients of childbearing potential, and electrocardiogram for patients over 50 or with cardiovascular risk factors. Some protocols also include baseline complete blood count and urinalysis, particularly if repeated or long-term treatment is anticipated.
Informed Consent
The informed consent process for ketamine therapy should address the off-label nature of treatment (for indications other than FDA-approved uses), the expected benefits and response rates, the common and serious potential side effects, alternative treatment options, the expected treatment course and frequency, restrictions on driving and operating machinery after treatment, and the plan for monitoring and follow-up. Consent should be documented in writing and revisited periodically during the treatment course, particularly if the treatment plan changes or new risks emerge.
Ongoing Monitoring During Treatment
Screening does not end with the initial evaluation. Patients receiving serial ketamine treatments require ongoing reassessment at regular intervals. This includes monitoring for emerging psychotic symptoms, signs of ketamine misuse or escalating at-home use for patients prescribed take-home formulations, interval changes in blood pressure or cardiovascular status, and lower urinary tract symptoms that may indicate early cystitis. A structured re-evaluation at every four to six sessions, with full vital signs and clinical assessment at each individual session, represents a reasonable standard of care.
References
- MedlinePlus: Ketamine Injection Drug Information — National Library of Medicine patient medication information including contraindications and precautions
- MedlinePlus: Esketamine Nasal Spray Drug Information — National Library of Medicine prescribing information for Spravato including REMS contraindications
- FDA MedWatch: Safety Information and Adverse Event Reporting — FDA safety reporting for drug contraindication-related adverse events
- DailyMed: FDA Drug Label Information — National Library of Medicine database for official drug labeling including contraindication listings
Share